Suggested remit: To appraise the clinical and cost effectiveness of asciminib within its marketing authorisation for treating Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in the chronic phase after two or more tyrosine kinase inhibitors.
Status In progress
Process STA 2018
ID number 3813

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
27 May 2021 - 25 June 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 October 2018 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance